Literature DB >> 6406646

The metabolism of dopamine by both forms of monoamine oxidase in the rat brain and its inhibition by cimoxatone.

C J Fowler, M S Benedetti.   

Abstract

In the rat brain, dopamine is metabolised by both A and B forms of monoamine oxidase (MAO), although the A form of the enzyme is the major component. The Km of MAO-A toward dopamine (120 microM) is lower than the Km of MAO-B toward this substrate (340 microM). The activity of MAO-A was lower in old rats than in young rats, and the same degree of decrease was found for 5-hydroxytryptamine as for dopamine as substrates for this enzyme form. The activity of MAO-B was higher in the old rats, the degree of increase being the same for dopamine as for beta-phenethylamine as substrates for this enzyme form. The Ki values of the inhibition of MAO-A by cimoxatone and MD770222 (the principal plasma metabolite of cimoxatone) were independent of the substrate used to assay for activity, but were lower than the Ki values for the inhibition of MAO-B by these compounds.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6406646     DOI: 10.1111/j.1471-4159.1983.tb08123.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  22 in total

1.  Effect of milacemide on extracellular and tissue concentrations of dopamine and 5-hydroxytryptamine in rat frontal cortex.

Authors:  J Semba; M Doheny; P N Patsalos; G Sarna; G Curzon
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

2.  Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset.

Authors:  Adjia Hamadjida; Stephen G Nuara; Cynthia Kwan; Imane Frouni; Dominique Bédard; Jim C Gourdon; Philippe Huot
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-07-03       Impact factor: 3.000

3.  Inhibition of MAO-B by (-)-deprenyl alters dopamine metabolism in the macaque (Macaca facicularis) brain.

Authors:  I A Paterson; B A Davis; D A Durden; A V Juorio; P H Yu; G Ivy; W Milgram; A Mendonca; P Wu; A A Boulton
Journal:  Neurochem Res       Date:  1995-12       Impact factor: 3.996

4.  Role of monoamine oxidase type A and B on the dopamine metabolism in discrete regions of the primate brain.

Authors:  M K Lakshmana; B S Rao; N K Dhingra; R Ravikumar; S Sudha; B L Meti; T R Raju
Journal:  Neurochem Res       Date:  1998-08       Impact factor: 3.996

5.  Estimation of the elimination half-life of the monoamine oxidase inhibitor cimoxatone in rat brain on the basis of ex vivo inhibition data.

Authors:  C J Fowler; M Strolin Benedetti; V Rovei
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1983 Oct-Dec       Impact factor: 2.441

6.  Effect of a reversible and selective MAO-A inhibitor (cimoxatone) on diurnal variation in plasma prolactin level in man.

Authors:  M Strolin Benedetti; A Eschalier; A Lesage; G Dordain; V Rovei; E Zarifian; P Dostert
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

7.  Rhesus monkey cerebrospinal fluid amine metabolite changes following treatment with the reversible monoamine oxidase type-A inhibitor cimoxatone.

Authors:  N A Garrick; T Seppala; M Linnoila; D L Murphy
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

8.  The deamination of noradrenaline and 5-hydroxytryptamine by rat brain and heart monoamine oxidase and their inhibition by cimoxatone, toloxatone and MD 770222.

Authors:  M Strolin Benedetti; T Boucher; C J Fowler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-08       Impact factor: 3.000

Review 9.  Platelet monoamine oxidase B: use and misuse.

Authors:  M B Youdim
Journal:  Experientia       Date:  1988-02-15

10.  Effects of ageing on the content in sulfur-containing amino acids in rat brain.

Authors:  M S Benedetti; A Russo; P Marrari; P Dostert
Journal:  J Neural Transm Gen Sect       Date:  1991
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.